Eyenovia, Inc. (EYEN)
After hours:
| Previous Close | 3.1800 |
| Open | 3.2500 |
| Bid | 3.3800 x 900 |
| Ask | 3.5900 x 4000 |
| Day's Range | 3.2293 - 3.6800 |
| 52 Week Range | 1.5000 - 3.6800 |
| Volume | |
| Avg. Volume | 206,893 |
| Market Cap | 127.508M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 |
- GlobeNewswire
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program Entered into co-development agreement with Formosa Pharmaceuticals Company to host conference call and webcast today, March 30th, at 4:30 pm ET NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN),
- GlobeNewswire
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ETNEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, Mar
- GlobeNewswire
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Stephen Benjamin, an independent director on the Company’s Board of Directors, is stepping down to assume the role of Head of the Wh
